AU2004206955A1 - Aptamer therapeutics useful in ocular pharmacotherapy - Google Patents

Aptamer therapeutics useful in ocular pharmacotherapy Download PDF

Info

Publication number: AU2004206955A1
Authority: AU; Australia
Prior art keywords: aptamer; composition; seq; binding; growth factor
Prior art date: 2003-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2004206955A

Other languages

English (en)

Inventor

David Epstein

Dilara Grate

Jeffrey Kurz

Nicholas Marsh

Thomas G. Mccauley

Charles Wilson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Archemix Corp

Original Assignee

Archemix Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-21

Filing date

2004-01-21

Publication date

2004-08-05

2004-01-21 Application filed by Archemix Corp filed Critical Archemix Corp

2004-08-05 Publication of AU2004206955A1 publication Critical patent/AU2004206955A1/en

Status Abandoned legal-status Critical Current

Links

108091023037 Aptamer Proteins 0.000 title claims description 315
239000003814 drug Substances 0.000 title description 84
238000001050 pharmacotherapy Methods 0.000 title description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 156
239000000203 mixture Substances 0.000 claims description 128
238000009739 binding Methods 0.000 claims description 112
230000027455 binding Effects 0.000 claims description 111
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 101
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 101
238000000034 method Methods 0.000 claims description 87
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
201000010099 disease Diseases 0.000 claims description 40
230000001225 therapeutic effect Effects 0.000 claims description 39
230000000694 effects Effects 0.000 claims description 38
238000011282 treatment Methods 0.000 claims description 34
125000003729 nucleotide group Chemical group 0.000 claims description 29
101000575066 Homo sapiens Mediator of RNA polymerase II transcription subunit 17 Proteins 0.000 claims description 28
102100025530 Mediator of RNA polymerase II transcription subunit 17 Human genes 0.000 claims description 28
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 28
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 28
230000004663 cell proliferation Effects 0.000 claims description 26
229920001515 polyalkylene glycol Polymers 0.000 claims description 26
238000002347 injection Methods 0.000 claims description 23
239000007924 injection Substances 0.000 claims description 23
208000010412 Glaucoma Diseases 0.000 claims description 21
-1 polyethylene Polymers 0.000 claims description 21
239000003102 growth factor Substances 0.000 claims description 19
230000001965 increasing effect Effects 0.000 claims description 18
210000001742 aqueous humor Anatomy 0.000 claims description 17
102000004127 Cytokines Human genes 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 16
208000035475 disorder Diseases 0.000 claims description 16
125000005647 linker group Chemical group 0.000 claims description 16
230000037390 scarring Effects 0.000 claims description 15
108090000695 Cytokines Proteins 0.000 claims description 13
230000004410 intraocular pressure Effects 0.000 claims description 13
102100037852 Insulin-like growth factor I Human genes 0.000 claims description 12
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
102000018697 Membrane Proteins Human genes 0.000 claims description 9
108010052285 Membrane Proteins Proteins 0.000 claims description 9
239000002202 Polyethylene glycol Substances 0.000 claims description 9
125000003827 glycol group Chemical group 0.000 claims description 8
230000001028 anti-proliverative effect Effects 0.000 claims description 7
102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 6
101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 6
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
239000003242 anti bacterial agent Substances 0.000 claims description 6
229940072041 transforming growth factor beta 2 Drugs 0.000 claims description 6
208000030533 eye disease Diseases 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
102100032817 Integrin alpha-5 Human genes 0.000 claims description 4
108010041014 Integrin alpha5 Proteins 0.000 claims description 4
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
239000002260 anti-inflammatory agent Substances 0.000 claims description 4
229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
229940121375 antifungal agent Drugs 0.000 claims description 4
239000003429 antifungal agent Substances 0.000 claims description 4
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 3
230000003834 intracellular effect Effects 0.000 claims description 3
239000003443 antiviral agent Substances 0.000 claims description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
239000004698 Polyethylene Substances 0.000 claims 2
208000035269 cancer or benign tumor Diseases 0.000 claims 2
239000008177 pharmaceutical agent Substances 0.000 claims 2
229920000573 polyethylene Polymers 0.000 claims 2
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 1
102000056172 Transforming growth factor beta-3 Human genes 0.000 claims 1
108090000097 Transforming growth factor beta-3 Proteins 0.000 claims 1
239000004037 angiogenesis inhibitor Substances 0.000 claims 1
239000003193 general anesthetic agent Substances 0.000 claims 1
229940099456 transforming growth factor beta 1 Drugs 0.000 claims 1
108020004707 nucleic acids Proteins 0.000 description 118
102000039446 nucleic acids Human genes 0.000 description 118
150000007523 nucleic acids Chemical class 0.000 description 116
RMWCNISNSABOOL-GRFIIANRSA-N [[(3r)-4-[[3-[(4-amino-4-oxobutyl)amino]-3-oxopropyl]amino]-3-hydroxy-2,2-dimethyl-4-oxobutoxy]-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCCC(N)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RMWCNISNSABOOL-GRFIIANRSA-N 0.000 description 90
210000004027 cell Anatomy 0.000 description 58
210000001508 eye Anatomy 0.000 description 47
239000003446 ligand Substances 0.000 description 46
108091034117 Oligonucleotide Proteins 0.000 description 42
150000001875 compounds Chemical class 0.000 description 32
102000004169 proteins and genes Human genes 0.000 description 32
108090000623 proteins and genes Proteins 0.000 description 32
210000001525 retina Anatomy 0.000 description 32
241000282414 Homo sapiens Species 0.000 description 31
235000018102 proteins Nutrition 0.000 description 30
206010012689 Diabetic retinopathy Diseases 0.000 description 29
229940124597 therapeutic agent Drugs 0.000 description 29
108010009583 Transforming Growth Factors Proteins 0.000 description 27
102000009618 Transforming Growth Factors Human genes 0.000 description 27
230000004048 modification Effects 0.000 description 27
238000012986 modification Methods 0.000 description 27
230000008569 process Effects 0.000 description 26
239000000243 solution Substances 0.000 description 26
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 24
229940079593 drug Drugs 0.000 description 24
102000005962 receptors Human genes 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 22
206010038934 Retinopathy proliferative Diseases 0.000 description 22
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 22
230000006785 proliferative vitreoretinopathy Effects 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 20
210000001519 tissue Anatomy 0.000 description 20
201000004569 Blindness Diseases 0.000 description 19
102220485938 Probable ATP-dependent RNA helicase DHX34_K94R_mutation Human genes 0.000 description 19
230000001404 mediated effect Effects 0.000 description 19
239000002773 nucleotide Substances 0.000 description 19
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 19
230000002062 proliferating effect Effects 0.000 description 18
238000003786 synthesis reaction Methods 0.000 description 18
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 17
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 17
238000001990 intravenous administration Methods 0.000 description 17
229920000642 polymer Polymers 0.000 description 17
230000035755 proliferation Effects 0.000 description 17
230000002207 retinal effect Effects 0.000 description 17
238000001356 surgical procedure Methods 0.000 description 16
238000007920 subcutaneous administration Methods 0.000 description 15
206010038848 Retinal detachment Diseases 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 14
230000004264 retinal detachment Effects 0.000 description 14
230000000087 stabilizing effect Effects 0.000 description 14
102100029880 Glycodelin Human genes 0.000 description 13
101000585553 Homo sapiens Glycodelin Proteins 0.000 description 13
238000010494 dissociation reaction Methods 0.000 description 13
230000005593 dissociations Effects 0.000 description 13
230000005012 migration Effects 0.000 description 13
238000013508 migration Methods 0.000 description 13
230000004393 visual impairment Effects 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
238000003556 assay Methods 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
239000012528 membrane Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
206010012601 diabetes mellitus Diseases 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
208000022873 Ocular disease Diseases 0.000 description 10
102220560186 Stromal cell-derived factor 1_R60K_mutation Human genes 0.000 description 10
230000033115 angiogenesis Effects 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
239000000539 dimer Substances 0.000 description 10
238000007912 intraperitoneal administration Methods 0.000 description 10
210000004379 membrane Anatomy 0.000 description 10
102220011217 rs281865122 Human genes 0.000 description 10
238000000638 solvent extraction Methods 0.000 description 10
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 9
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
102000001708 Protein Isoforms Human genes 0.000 description 9
108010029485 Protein Isoforms Proteins 0.000 description 9
210000004204 blood vessel Anatomy 0.000 description 9
229960002949 fluorouracil Drugs 0.000 description 9
230000001976 improved effect Effects 0.000 description 9
238000010348 incorporation Methods 0.000 description 9
108091008104 nucleic acid aptamers Proteins 0.000 description 9
241000894007 species Species 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
230000003321 amplification Effects 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
230000003993 interaction Effects 0.000 description 8
238000003199 nucleic acid amplification method Methods 0.000 description 8
230000007170 pathology Effects 0.000 description 8
210000002381 plasma Anatomy 0.000 description 8
231100000241 scar Toxicity 0.000 description 8
235000002639 sodium chloride Nutrition 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 7
108020004414 DNA Proteins 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 7
241000700159 Rattus Species 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
238000002648 combination therapy Methods 0.000 description 7
230000004438 eyesight Effects 0.000 description 7
210000002950 fibroblast Anatomy 0.000 description 7
239000012530 fluid Substances 0.000 description 7
210000004498 neuroglial cell Anatomy 0.000 description 7
230000008506 pathogenesis Effects 0.000 description 7
230000035515 penetration Effects 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
150000003230 pyrimidines Chemical group 0.000 description 7
239000000725 suspension Substances 0.000 description 7
230000009885 systemic effect Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
210000001585 trabecular meshwork Anatomy 0.000 description 7
101150106709 ARC1 gene Proteins 0.000 description 6
101100013575 Arabidopsis thaliana FTSHI1 gene Proteins 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
102000004877 Insulin Human genes 0.000 description 6
108090001061 Insulin Proteins 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
239000000020 Nitrocellulose Substances 0.000 description 6
101710163270 Nuclease Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000002256 antimetabolite Substances 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
230000006378 damage Effects 0.000 description 6
230000007423 decrease Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
210000002889 endothelial cell Anatomy 0.000 description 6
230000002349 favourable effect Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
230000012010 growth Effects 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
229940125396 insulin Drugs 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
229920001220 nitrocellulos Polymers 0.000 description 6
230000035699 permeability Effects 0.000 description 6
239000002336 ribonucleotide Substances 0.000 description 6
210000003786 sclera Anatomy 0.000 description 6
230000009870 specific binding Effects 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000000699 topical effect Effects 0.000 description 6
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
108091028664 Ribonucleotide Proteins 0.000 description 5
241000283984 Rodentia Species 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
210000004155 blood-retinal barrier Anatomy 0.000 description 5
230000004378 blood-retinal barrier Effects 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
150000002009 diols Chemical class 0.000 description 5
238000001914 filtration Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000000710 homodimer Substances 0.000 description 5
208000018769 loss of vision Diseases 0.000 description 5
231100000864 loss of vision Toxicity 0.000 description 5
239000000463 material Substances 0.000 description 5
230000003285 pharmacodynamic effect Effects 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000029663 wound healing Effects 0.000 description 5
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
108010005094 Advanced Glycation End Products Proteins 0.000 description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
108060002716 Exonuclease Proteins 0.000 description 4
206010016654 Fibrosis Diseases 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
206010024404 Leukostasis Diseases 0.000 description 4
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
206010029113 Neovascularisation Diseases 0.000 description 4
241000772415 Neovison vison Species 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
208000007135 Retinal Neovascularization Diseases 0.000 description 4
208000002367 Retinal Perforations Diseases 0.000 description 4
102100040247 Tumor necrosis factor Human genes 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
230000000340 anti-metabolite Effects 0.000 description 4
229940100197 antimetabolite Drugs 0.000 description 4
238000013459 approach Methods 0.000 description 4
201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
230000008827 biological function Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000000423 cell based assay Methods 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
230000008602 contraction Effects 0.000 description 4
230000032459 dedifferentiation Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
102000013165 exonuclease Human genes 0.000 description 4
230000004761 fibrosis Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
102000028416 insulin-like growth factor binding Human genes 0.000 description 4
108091022911 insulin-like growth factor binding Proteins 0.000 description 4
150000002605 large molecules Chemical class 0.000 description 4
150000002634 lipophilic molecules Chemical class 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000003226 mitogen Substances 0.000 description 4
229960004857 mitomycin Drugs 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
230000035772 mutation Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000001542 size-exclusion chromatography Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000008107 starch Substances 0.000 description 4
230000008685 targeting Effects 0.000 description 4
210000004127 vitreous body Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
244000202285 Acrocomia mexicana Species 0.000 description 3
235000003625 Acrocomia mexicana Nutrition 0.000 description 3
102000007469 Actins Human genes 0.000 description 3
108010085238 Actins Proteins 0.000 description 3
206010002329 Aneurysm Diseases 0.000 description 3
102000009840 Angiopoietins Human genes 0.000 description 3
108010009906 Angiopoietins Proteins 0.000 description 3
108010081589 Becaplermin Proteins 0.000 description 3
102000000844 Cell Surface Receptors Human genes 0.000 description 3
108010001857 Cell Surface Receptors Proteins 0.000 description 3
208000017667 Chronic Disease Diseases 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010009202 Growth Factor Receptors Proteins 0.000 description 3
102000009465 Growth Factor Receptors Human genes 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 3
101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 3
101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
208000009857 Microaneurysm Diseases 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102100029139 Peroxiredoxin-1 Human genes 0.000 description 3
229920000153 Povidone-iodine Polymers 0.000 description 3
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 3
108091008605 VEGF receptors Proteins 0.000 description 3
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000013543 active substance Substances 0.000 description 3
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
229920001400 block copolymer Polymers 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000000872 buffer Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
239000000512 collagen gel Substances 0.000 description 3
108091036078 conserved sequence Proteins 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
108010057085 cytokine receptors Proteins 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
230000001066 destructive effect Effects 0.000 description 3
230000005750 disease progression Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
239000003889 eye drop Substances 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007972 injectable composition Substances 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
238000002515 oligonucleotide synthesis Methods 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
150000008300 phosphoramidites Chemical class 0.000 description 3
229960001621 povidone-iodine Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000004224 protection Effects 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
150000003212 purines Chemical group 0.000 description 3
239000002719 pyrimidine nucleotide Substances 0.000 description 3
239000008175 ready-to-use sterile solution Substances 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
208000037803 restenosis Diseases 0.000 description 3
210000003583 retinal pigment epithelium Anatomy 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000012475 sodium chloride buffer Substances 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
239000000758 substrate Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
238000007910 systemic administration Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000009772 tissue formation Effects 0.000 description 3
238000002691 topical anesthesia Methods 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
229960001005 tuberculin Drugs 0.000 description 3
230000002792 vascular Effects 0.000 description 3
238000009736 wetting Methods 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
101800003158 5 kDa peptide Proteins 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
238000010599 BrdU assay Methods 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000001351 Epiretinal Membrane Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
101000950648 Homo sapiens Malectin Proteins 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
101150088952 IGF1 gene Proteins 0.000 description 2
102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
206010023421 Kidney fibrosis Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010025421 Macule Diseases 0.000 description 2
102100037750 Malectin Human genes 0.000 description 2
229910021380 Manganese Chloride Inorganic materials 0.000 description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
102000012750 Membrane Glycoproteins Human genes 0.000 description 2
108010090054 Membrane Glycoproteins Proteins 0.000 description 2
108091008606 PDGF receptors Proteins 0.000 description 2
229910019142 PO4 Chemical group 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
108010076181 Proinsulin Proteins 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
108091008103 RNA aptamers Proteins 0.000 description 2
206010038897 Retinal tear Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
101710137500 T7 RNA polymerase Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
208000000208 Wet Macular Degeneration Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
206010064930 age-related macular degeneration Diseases 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000002424 anti-apoptotic effect Effects 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
208000002352 blister Diseases 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
208000037887 cell injury Diseases 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
210000000795 conjunctiva Anatomy 0.000 description 2
210000001608 connective tissue cell Anatomy 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
150000002243 furanoses Chemical group 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
230000036541 health Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
210000003000 inclusion body Anatomy 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000011565 manganese chloride Substances 0.000 description 2
235000002867 manganese chloride Nutrition 0.000 description 2
229940099607 manganese chloride Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000013507 mapping Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000003607 modifier Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000004126 nerve fiber Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
231100000956 nontoxicity Toxicity 0.000 description 2
230000009701 normal cell proliferation Effects 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000003668 pericyte Anatomy 0.000 description 2
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000008196 pharmacological composition Substances 0.000 description 2
239000010452 phosphate Chemical group 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
230000036515 potency Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
238000011555 rabbit model Methods 0.000 description 2
229920005604 random copolymer Polymers 0.000 description 2
230000004254 retinal expression Effects 0.000 description 2
208000032253 retinal ischemia Diseases 0.000 description 2
239000000790 retinal pigment Substances 0.000 description 2
230000004233 retinal vasculature Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
102000035025 signaling receptors Human genes 0.000 description 2
108091005475 signaling receptors Proteins 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
210000001760 tenon capsule Anatomy 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
RGNOTKMIMZMNRX-XVFCMESISA-N 2-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-one Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RGNOTKMIMZMNRX-XVFCMESISA-N 0.000 description 1
ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical class BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical class IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101150046212 ARC2 gene Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
101150019028 Antp gene Proteins 0.000 description 1
206010002945 Aphakia Diseases 0.000 description 1
102100021723 Arginase-1 Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010010719 Conjunctival haemorrhage Diseases 0.000 description 1
206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000008069 Geographic Atrophy Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 1
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 1
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
208000001344 Macular Edema Diseases 0.000 description 1
206010025415 Macular oedema Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
241000283923 Marmota monax Species 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
229940121849 Mitotic inhibitor Drugs 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
208000033796 Pseudophakia Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
208000034699 Vitreous floaters Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
229940059260 amidate Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003510 anti-fibrotic effect Effects 0.000 description 1
229940093906 antibiotic and corticosteroids Drugs 0.000 description 1
229940124691 antibody therapeutics Drugs 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
201000007917 background diabetic retinopathy Diseases 0.000 description 1
230000008721 basement membrane thickening Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000004240 ciliary body Anatomy 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
208000021921 corneal disease Diseases 0.000 description 1
201000007717 corneal ulcer Diseases 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000011262 co‐therapy Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
229960001815 cyclopentolate Drugs 0.000 description 1
229940124570 cycloplegic agent Drugs 0.000 description 1
230000003500 cycloplegic effect Effects 0.000 description 1
208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
150000001985 dialkylglycerols Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000008556 epithelial cell proliferation Effects 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000023747 glial cell migration Effects 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
229920000140 heteropolymer Polymers 0.000 description 1
230000004402 high myopia Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000058223 human VEGFA Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
201000010230 macular retinal edema Diseases 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002406 microsurgery Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000037257 muscle growth Effects 0.000 description 1
210000000651 myofibroblast Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
210000005157 neural retina Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000013546 non-drug therapy Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
102000044158 nucleic acid binding protein Human genes 0.000 description 1
108700020942 nucleic acid binding protein Proteins 0.000 description 1
230000005257 nucleotidylation Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
238000002823 phage display Methods 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
125000005642 phosphothioate group Chemical group 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000000649 photocoagulation Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
108010017843 platelet-derived growth factor A Proteins 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920002721 polycyanoacrylate Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000011165 process development Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000004064 recycling Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012772 sequence design Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000003356 suture material Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
OJNFDOAQUXJWED-XCSFTKGKSA-N tatp Chemical compound NC(=S)C1=CC=C[N+]([C@H]2[C@@H]([C@@H](O)[C@H](COP([O-])(=O)O[P@@](O)(=O)OC[C@H]3[C@@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 OJNFDOAQUXJWED-XCSFTKGKSA-N 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
229940126702 topical medication Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000004382 visual function Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Cardiology (AREA)
Virology (AREA)
Biochemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

AU2004206955A 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy Abandoned AU2004206955A1 (en)

Applications Claiming Priority (21)

Application Number	Priority Date	Filing Date	Title
US44134703P	2003-01-21	2003-01-21
US60/441,347		2003-01-21
US46309503P	2003-04-15	2003-04-15
US60/463,095		2003-04-15
US46417903P	2003-04-21	2003-04-21
US60/464,179		2003-04-21
US46505503P	2003-04-23	2003-04-23
US60/465,055		2003-04-23
US46962803P	2003-05-08	2003-05-08
US60/469,628		2003-05-08
US47468003P	2003-05-29	2003-05-29
US60/474,680		2003-05-29
US49101903P	2003-07-29	2003-07-29
US60/491,019		2003-07-29
US51207103P	2003-10-17	2003-10-17
US60/512,071		2003-10-17
US53704504P	2004-01-16	2004-01-16
US53720104P	2004-01-16	2004-01-16
US60/537,201		2004-01-16
US60/537,045		2004-01-16
PCT/US2004/001661 WO2004064760A2 (fr)	2003-01-21	2004-01-21	Agents therapeutiques aptameres utiles dans la pharmacotherapie oculaire

Publications (1)

Publication Number	Publication Date
AU2004206955A1 true AU2004206955A1 (en)	2004-08-05

Family

ID=32777434

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004206955A Abandoned AU2004206955A1 (en)	2003-01-21	2004-01-21	Aptamer therapeutics useful in ocular pharmacotherapy

Country Status (5)

Country	Link
EP (1)	EP1606301A4 (fr)
JP (1)	JP2006516288A (fr)
AU (1)	AU2004206955A1 (fr)
CA (1)	CA2513004A1 (fr)
WO (1)	WO2004064760A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070166741A1 (en)	1998-12-14	2007-07-19	Somalogic, Incorporated	Multiplexed analyses of test samples
US10100316B2 (en)	2002-11-21	2018-10-16	Archemix Llc	Aptamers comprising CPG motifs
US8039443B2 (en)	2002-11-21	2011-10-18	Archemix Corporation	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en)	2002-11-21	2014-10-07	Archemix Llc	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7803931B2 (en)	2004-02-12	2010-09-28	Archemix Corp.	Aptamer therapeutics useful in the treatment of complement-related disorders
EP1737497A2 (fr) *	2004-04-13	2007-01-03	(Osi) Eyetech, Inc.	Conjugues biologiquement actifs ameliores
EP3034089A1 (fr) *	2004-11-02	2016-06-22	Archemix LLC	Aptameres stabilises pour plaquettes derives du facteur de croissance et leur utilisation en tant que produits therapeutiques oncologiques
WO2006119643A1 (fr) *	2005-05-12	2006-11-16	Replicor Inc.	Molecules contre l'angiogenese oculaire et leurs utilisations
HUE026496T2 (en) *	2006-03-08	2016-06-28	Archemix Llc	Complement-binding aptamers and anti-C5 agents for treating eye diseases
CN108165548B (zh)	2008-09-22	2022-10-14	菲奥医药公司	减小大小的自递送RNAi化合物
JP2010100615A (ja) *	2008-09-25	2010-05-06	Santen Pharmaceut Co Ltd	ポリアルキレングリコールを有効成分として含有する網膜疾患の予防又は治療剤
US9745574B2 (en)	2009-02-04	2017-08-29	Rxi Pharmaceuticals Corporation	RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8993715B2 (en) *	2009-07-06	2015-03-31	Canon Kabushiki Kaisha	Labeled protein and method for obtaining the same
JP6041373B2 (ja) *	2010-02-01	2016-12-07	Ｎｅｃソリューションイノベータ株式会社	ＴＮＦ−αに結合するアプタマー分子
US9080171B2 (en)	2010-03-24	2015-07-14	RXi Parmaceuticals Corporation	Reduced size self-delivering RNAi compounds
CN103200945B (zh)	2010-03-24	2016-07-06	雷克西制药公司	眼部症候中的rna干扰
WO2013149086A1 (fr)	2012-03-28	2013-10-03	Somalogic, Inc.	Aptamères dirigés contre pdgf et vegf et leur utilisation dans le traitement d'états à médiation par pdgf et vegf
MX2016000364A (es) *	2013-07-12	2016-05-09	Ophthotech Corp	Metodos para tratar o prevenir afecciones oftalmologicas.
CA3221709A1 (fr)	2013-09-09	2015-03-12	Somalogic Operating Co., Inc.	Aptameres de pdgf et vegf presentant une stabilite amelioree et leur utilisation dans le traitement de maladies et de troubles medies par pdgf et vegf
CN105960265A (zh) *	2013-12-04	2016-09-21	阿克赛医药公司	利用经化学修饰的寡核苷酸处理伤口愈合的方法
CA2947270A1 (fr)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Procedes de traitement du cancer au moyen d'un acide nucleique deciblage de mdm2 ou mycn
AU2016364431B2 (en)	2015-12-04	2020-08-27	Zenyaku Kogyo Co., Ltd.	Anti-IL-17 aptamer having improved retention in blood
CA3012718A1 (fr)	2016-02-08	2017-08-17	Vitrisa Therapeutics, Inc.	Compositions a demi-vie intravitreenne amelioree et leurs utilisations
WO2018148333A1 (fr) *	2017-02-08	2018-08-16	Vitrisa Therapeutics, Inc.	Compositions à demi-vie intravitréenne améliorée et utilisations associées
EP3740481B9 (fr)	2018-01-19	2024-10-23	Cytokinetics, Inc.	Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
EP3814343B1 (fr)	2018-06-26	2023-01-11	Cytokinetics, Inc.	Inhibiteurs de sarcomères cardiaques
EP3814342B1 (fr)	2018-06-26	2022-07-27	Cytokinetics, Inc.	Inhibiteurs de sarcomères cardiaques
WO2020120256A1 (fr) *	2018-12-11	2020-06-18	Université De Strasbourg	Aptamère et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6346611B1 (en) *	1990-06-11	2002-02-12	Gilead Sciences, Inc.	High affinity TGfβ nucleic acid ligands and inhibitors
US5811533A (en) *	1990-06-11	1998-09-22	Nexstar Pharmaceuticals, Inc.	High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6458559B1 (en) *	1998-04-22	2002-10-01	Cornell Research Foundation, Inc.	Multivalent RNA aptamers and their expression in multicellular organisms
ATE406914T1 (de) *	2000-02-10	2008-09-15	Massachusetts Eye & Ear Infirm	Photodynamische therapie zur behandlung von augenerkrankungen

2004
- 2004-01-21 EP EP04704120A patent/EP1606301A4/fr not_active Withdrawn
- 2004-01-21 WO PCT/US2004/001661 patent/WO2004064760A2/fr not_active Ceased
- 2004-01-21 CA CA002513004A patent/CA2513004A1/fr not_active Abandoned
- 2004-01-21 JP JP2006501092A patent/JP2006516288A/ja active Pending
- 2004-01-21 AU AU2004206955A patent/AU2004206955A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1606301A2 (fr)	2005-12-21
EP1606301A4 (fr)	2006-06-14
WO2004064760A2 (fr)	2004-08-05
JP2006516288A (ja)	2006-06-29
CA2513004A1 (fr)	2004-08-05
WO2004064760A3 (fr)	2005-10-27

Publication	Publication Date	Title
AU2004206955A1 (en)	2004-08-05	Aptamer therapeutics useful in ocular pharmacotherapy
US20040253243A1 (en)	2004-12-16	Aptamer therapeutics useful in ocular pharmacotherapy
AU2007223796B2 (en)	2013-01-24	Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US20070066551A1 (en)	2007-03-22	Aptamer medicinal chemistry
US8318923B2 (en)	2012-11-27	Nucleic acid modulators of glycoprotein VI
EP2623601B1 (fr)	2015-02-18	Aptamères stabilisés pour facteur de croissance dérivé de plaquette et leur utilisation en tant que traitements d'oncologie
US11466276B2 (en)	2022-10-11	Stem-loop compositions and methods for inhibiting factor D
WO2018136831A1 (fr)	2018-07-26	Compositions de pseudo-nœuds et méthodes pour inhiber le facteur d
JP2023516392A (ja)	2023-04-19	アプタマーおよびその使用
WO2019022986A1 (fr)	2019-01-31	Compositions d'acide nucléique et procédés d'inhibition du facteur d
AU2022202115A1 (en)	2022-04-14	Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US8889645B2 (en)	2014-11-18	Nucleic acid modulators of glycoprotein VI
US8889646B2 (en)	2014-11-18	Nucleic acid modulators of glycoprotein VI
US20090018093A1 (en)	2009-01-15	Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics
AU2020201145A1 (en)	2020-03-05	Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
CN1984920A (zh)	2007-06-20	应用于眼疾的药物疗法中的适合体治疗剂
HK1146296A (en)	2011-05-20	C5a binding nucleic acids

Legal Events

Date	Code	Title	Description
2009-08-13	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application